Forteo teriparatide: Post-marketing study data

In a double-blind trial in 304 evaluable patients, Forteo significantly increased lumbar spine BMD vs. Fosamax alendronate after 18 months (8.2% vs. 3.9%, p<0.001). At 18 months, the mean increase in...